CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX – Get Free Report) was the target of a large decline in short interest in the month of February. As of February 13th, there was short interest totaling 40,001 shares, a decline of 46.7% from the January 29th total of 74,980 shares. Based on an average daily trading volume, of 2,958,451 shares, the short-interest ratio is presently 0.0 days. Based on an average daily trading volume, of 2,958,451 shares, the short-interest ratio is presently 0.0 days.
CNBX Pharmaceuticals Price Performance
Shares of CNBX opened at $0.00 on Monday. CNBX Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $0.01.
About CNBX Pharmaceuticals
CNBX Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the research and development of synthetic cannabinoid-based drug candidates. The company’s proprietary platform applies medicinal chemistry techniques to design novel small-molecule analogs of naturally occurring cannabinoids, aiming to improve efficacy and safety compared with existing therapies. Its pipeline includes multiple preclinical compounds targeting neuropathic and chronic pain, with a goal of advancing these candidates through IND-enabling studies.
Headquartered in Costa Mesa, California, CNBX Pharmaceuticals collaborates with contract research organizations and academic partners to conduct pharmacology and toxicology studies as well as scale up manufacturing processes.
Featured Stories
- Five stocks we like better than CNBX Pharmaceuticals
- Silver Crossed $100: Is the $500 surge next? (Join us March 4)
- America’s 1776 happening again
- Unlocked: Elon Musk’s Next Big IPO
- Silver paying 20% dividend. Plus 68% share gains
- REVEALED: Something Big Happening Behind White House Doors
Receive News & Ratings for CNBX Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNBX Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
